PHARMACOKINETIC AND PHARMACODYNAMIC ACTIVITIES OF CIPROFLOXACIN AGAINST STRAINS OF STREPTOCOCCUS-PNEUMONIAE, STAPHYLOCOCCUS-AUREUS, AND PSEUDOMONAS-AERUGINOSA FOR WHICH MICS ARE SIMILAR

被引:70
作者
HYATT, JM [1 ]
NIX, DE [1 ]
SCHENTAG, JJ [1 ]
机构
[1] SUNY BUFFALO,SCH PHARM,CTR CLIN PHARM RES,BUFFALO,NY 14209
关键词
D O I
10.1128/AAC.38.12.2730
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The serum bactericidal activity of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar (0.4 mu g/ml) was assessed with serum ultrafiltrates from five healthy volunteers receiving ciprofloxacin at 400 mg intravenously every 8 h. In addition, human serum was supplemented with ciprofloxacin to achieve a mean steady-state concentration (C-ss) that might be achieved in patients with renal failure, with total clearances of 3 to 4 liters/h (elimination rate constant, 0.08 h(-1)). The area under the inhibitory titer curve from 0 to 24 h (AUIC(24)) and the area under the bactericidal titer curve from 0 to 24 h (AUBC(24)) were both measured and predicted as the area under the concentration-time curve from 0 to 24 h (AUC(24))/MIC and AUC(24)/MBC, respectively. We previously demonstrated that a breakpoint AUC(24)/MIC of 125 for ciprofloxacin had a significantly higher probability of treatment success than lower values, with 250 to 500 being optimal. Volunteer sera (mean C-ss, 1.55 to 2.48 mu g/ml) achieved AUC,MICs of 90 to 145. Supplemented serum (mean C-ss, 6.00 to 7.42 mu g/ml) achieved AUC(24)/MICs of 350 to 450. Correlation coefficients for measured and predicted values of AUC(24)/MIC and AUC(24)/MBC mere 0.826 and 0.941, respectively. The mean percent errors were not significantly different from zero for either AUIC(24) or AUBC(24) values (P > 0.1, P > 0.4). Time-kill curve studies were performed with low (1.55 to 2.48 mu g/ml), intermediate (6.00 to 7.42 mu g/ml), and high (15 to 25 mu g/ml) concentrations of ciprofloxacin for the three organisms. At low concentrations (3 to 6 times the MIC) AUC(24)/MICs were < 125 for two of five volunteers and the killing rates were considerably more rapid for P. aeruginosa than for S. pneumoniae or S. aureus. Intermediate concentrations (15 to 18 times the MIC) achieved optimal AUC(24)/MICs, and the killing rates were similar for the three organisms. A paradoxical decrease in the killing rate was seen at high concentrations (35 to 60 times the MIC). At clinically achievable concentrations, ciprofloxacin killed P. aeruginosa more rapidly than it did either S. pneumoniae or S. aureus.
引用
收藏
页码:2730 / 2737
页数:8
相关论文
共 16 条
[1]   ANALYSIS OF A NEW METHOD FOR ASSESSING ACTIVITY OF COMBINATIONS OF ANTIMICROBIALS - AREA UNDER THE BACTERICIDAL ACTIVITY CURVE [J].
BARRIERE, SL ;
ELY, E ;
KAPUSNIK, JE ;
GAMBERTOGLIO, JG .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 16 (01) :49-59
[2]   CORRELATION OF PREDICTED SERUM BACTERICIDAL ACTIVITIES AND VALUES MEASURED IN VOLUNTEERS [J].
DRUSANO, G ;
STANDIFORD, H ;
RYAN, P ;
MCNAMEE, W ;
TATEM, B ;
SCHIMPFF, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1986, 5 (01) :88-92
[3]   PHARMACODYNAMICS OF A FLUOROQUINOLONE ANTIMICROBIAL AGENT IN A NEUTROPENIC RAT MODEL OF PSEUDOMONAS SEPSIS [J].
DRUSANO, GL ;
JOHNSON, DE ;
ROSEN, M ;
STANDIFORD, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :483-490
[5]   THE INHIBITORY QUOTIENT - A METHOD FOR INTERPRETING MINIMUM INHIBITORY CONCENTRATION DATA [J].
ELLNER, PD ;
NEU, HC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1981, 246 (14) :1575-1578
[6]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[7]   USE OF SERUM ULTRAFILTRATE IN THE SERUM DILUTION TEST [J].
LEGGETT, JE ;
WOLZ, SA ;
CRAIG, WA .
JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (04) :616-623
[8]   METHOD FOR RELIABLE DETERMINATION OF MINIMAL LETHAL ANTIBIOTIC CONCENTRATIONS [J].
PEARSON, RD ;
STEIGBIGEL, RT ;
DAVIS, HT ;
CHAPMAN, SW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (05) :699-708
[9]   EVALUATION OF INTRAVENOUS CIPROFLOXACIN IN PATIENTS WITH NOSOCOMIAL LOWER RESPIRATORY-TRACT INFECTIONS - IMPACT OF PLASMA-CONCENTRATIONS, ORGANISM, MINIMUM INHIBITORY CONCENTRATION, AND CLINICAL CONDITION ON BACTERIAL ERADICATION [J].
PELOQUIN, CA ;
CUMBO, TJ ;
NIX, DE ;
SANDS, MF ;
SCHENTAG, JJ .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (10) :2269-2273
[10]   ROLE FOR DUAL INDIVIDUALIZATION WITH CEFMENOXIME [J].
SCHENTAG, JJ ;
SMITH, IL ;
SWANSON, DJ ;
DEANGELIS, C ;
FRACASSO, JE ;
VARI, A ;
VANCE, JW .
AMERICAN JOURNAL OF MEDICINE, 1984, 77 (6A) :43-50